Abstract | BACKGROUND: The optimal management of patients with reflux-associated laryngitis is unclear. We performed a placebo-controlled crossover trial in patients with proven reflux disease and associated laryngitis to determine the effect of pantoprazole and to gain information on the natural course of the disease. METHODS: Sixty-two consecutive non-smoking patients with hoarseness and proven laryngitis were examined. Scores with respect to the larynx and for subjective complaints were determined and 24-h pH-metry to assess acid reflux in the lower oesophagus and pharynx was performed. Patients with pathologic reflux were given the chance to enter a double-blinded randomized crossover trial with pantoprazole 40 mg b.i.d. and placebo for a duration of 3 months each, separated by a 2-week washout period. RESULTS: Twenty-four of 62 patients showed pathological reflux; 21 patients were included in the study and 14 concluded all parts of the study. Both pantoprazole and placebo resulted in a marked improvement in laryngitis scores (decrease of 8.0 +/- 1.4 versus 5.6 +/- 2.6; no significant difference between the 2 treatments) and symptoms after the first 3 months (decrease of oesophageal symptom score of 2.2 +/- 1.4 versus 5.4 +/- 2.8; decrease of laryngeal scores of 8.3 +/- 3.6 versus 10.3 +/- 3.9; also no significant difference between the 2 treatments). A second pH-metry 2 weeks thereafter proved the persistence of reflux in most of these patients. Switching to pantoprazole led to a further improvement of scores. In the group switched to placebo there was recurrence only in a minority of patients. CONCLUSIONS: The self-limited nature of reflux-associated laryngitis in non-smokers is largely underestimated. Laryngitis improves despite the persistence of reflux. Pantoprazole may be helpful especially in relieving acute symptoms, but the advantage of long-term treatment over placebo has been greatly overestimated.
|
Authors | A J Eherer, W Habermann, H F Hammer, K Kiesler, G Friedrich, G J Krejs |
Journal | Scandinavian journal of gastroenterology
(Scand J Gastroenterol)
Vol. 38
Issue 5
Pg. 462-7
(May 2003)
ISSN: 0036-5521 [Print] England |
PMID | 12795454
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Anti-Ulcer Agents
- Benzimidazoles
- Proton Pump Inhibitors
- Sulfoxides
- Pantoprazole
- Omeprazole
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Adult
- Aged
- Anti-Ulcer Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Cross-Over Studies
- Double-Blind Method
- Female
- Gastroesophageal Reflux
(complications, drug therapy)
- Humans
- Laryngitis
(drug therapy, etiology)
- Male
- Middle Aged
- Omeprazole
(analogs & derivatives)
- Pantoprazole
- Proton Pump Inhibitors
- Recurrence
- Severity of Illness Index
- Sulfoxides
(therapeutic use)
|